An αv-RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and Opportunities.
暂无分享,去创建一个
Joelle Le | S. Macdonald | R. Hatley | R. Slack | P. Lukey | S. Ludbrook
[1] W. Kaelin,et al. Common pitfalls in preclinical cancer target validation , 2017, Nature Reviews Cancer.
[2] R. Chambers,et al. An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis , 2017, American journal of respiratory cell and molecular biology.
[3] Niki Prakoura,et al. NFκB-Induced Periostin Activates Integrin-β3 Signaling to Promote Renal Injury in GN. , 2017, Journal of the American Society of Nephrology : JASN.
[4] Lisa M. Miller,et al. Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins. , 2017, Journal of medicinal chemistry.
[5] Benjamin Geiger,et al. A Comprehensive Evaluation of the Activity and Selectivity Profile of Ligands for RGD-binding Integrins , 2017, Scientific Reports.
[6] J. Schwarzbauer,et al. Minireview: Fibronectin in retinal disease , 2017, Experimental biology and medicine.
[7] M. Gore,et al. Randomized phase II study of the safety and efficacy of a human anti-{alpha}v integrin monoclonal antibody (CNTO 95) alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: 12-month results , 2016 .
[8] Zhiwei Yang,et al. Zwitterionic structures: from physicochemical properties toward computer-aided drug designs. , 2016, Future medicinal chemistry.
[9] R. Harrison,et al. Phase II and phase III failures: 2013–2015 , 2016, Nature Reviews Drug Discovery.
[10] R. Slack,et al. Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand. , 2016, Biochemical pharmacology.
[11] W. DeGrado,et al. Exploring N-Arylsulfonyl-l-proline Scaffold as a Platform for Potent and Selective αvβ1 Integrin Inhibitors. , 2016, ACS medicinal chemistry letters.
[12] Niroshini Nirmalan,et al. “Omics”-Informed Drug and Biomarker Discovery: Opportunities, Challenges and Future Perspectives , 2016, Proteomes.
[13] S. Lynn,et al. Synthesis and determination of absolute configuration of a non-peptidic αvβ6 integrin antagonist for the treatment of idiopathic pulmonary fibrosis. , 2016, Organic & biomolecular chemistry.
[14] N. Henderson,et al. αv integrins: key regulators of tissue fibrosis , 2016, Cell and Tissue Research.
[15] Rachel C Chambers,et al. Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF , 2016, Thorax.
[16] B. Neuschwander‐Tetri,et al. Inhibitors of Arg-Gly-Asp-Binding Integrins Reduce Development of Pancreatic Fibrosis in Mice , 2016, Cellular and molecular gastroenterology and hepatology.
[17] K. Miller,et al. Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer , 2016, Clinical Cancer Research.
[18] Joachim P. Spatz,et al. In vitro cancer cell-ECM interactions inform in vivo cancer treatment. , 2016, Advanced drug delivery reviews.
[19] H. Kessler,et al. Kleine Ursache, große Wirkung: Modifikation der Guanidiniumgruppe im RGD‐Motiv reguliert die Integrinsubtypselektivität , 2016 .
[20] E. Novellino,et al. Stabile Peptide statt “gestapelte Peptide”: hochaffine αvβ6‐selektive Integrinliganden , 2016 .
[21] E. Novellino,et al. Stable Peptides Instead of Stapled Peptides: Highly Potent αvβ6-Selective Integrin Ligands. , 2016, Angewandte Chemie.
[22] H. Kessler,et al. Small Cause, Great Impact: Modification of the Guanidine Group in the RGD Motif Controls Integrin Subtype Selectivity. , 2016, Angewandte Chemie.
[23] J. Schellens,et al. A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies , 2016, Investigational New Drugs.
[24] D. Flint,et al. Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2 , 2016, Pharmacology.
[25] Zu-hua Gao,et al. Arginine-Glycine-Aspartate–Binding Integrins as Therapeutic and Diagnostic Targets , 2016, American journal of therapeutics.
[26] Beiyan Zou,et al. Investigation of miscellaneous hERG inhibition in large diverse compound collection using automated patch-clamp assay , 2016, Acta Pharmacologica Sinica.
[27] J. Gauldie,et al. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox , 2015, Nature Reviews Drug Discovery.
[28] H. R. Cheruku,et al. Integrin αvβ6 sets the stage for colorectal cancer metastasis , 2015, Cancer and Metastasis Reviews.
[29] C. Prakash,et al. Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integrin Antagonist , 2015, Drug Metabolism and Disposition.
[30] John P. Overington,et al. The promise and peril of chemical probes. , 2015, Nature chemical biology.
[31] Katie Kingwell. Fibrotic diseases: New tools to target an elusive integrin , 2015, Nature Reviews Drug Discovery.
[32] R. M. Owen,et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies , 2015, Nature Reviews Drug Discovery.
[33] Paul D Leeson,et al. Molecular Property Design: Does Everyone Get It? , 2015, ACS medicinal chemistry letters.
[34] W. DeGrado,et al. The αvβ1 integrin plays a critical in vivo role in tissue fibrosis , 2015, Science Translational Medicine.
[35] L. McIntosh,et al. Arginine: Its pKa value revisited , 2015, Protein science : a publication of the Protein Society.
[36] L. Duong,et al. Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis , 2015, Oncology reports.
[37] C. Bokemeyer,et al. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] T. Springer,et al. Structural determinants of integrin β-subunit specificity for latent TGF-β , 2014, Nature Structural &Molecular Biology.
[39] B. Coller,et al. RUC-4: A Novel &agr;IIb&bgr;3 Antagonist for Prehospital Therapy of Myocardial Infarction , 2014, Arteriosclerosis, thrombosis, and vascular biology.
[40] M. Fray,et al. Structure Activity Relationships of αv Integrin Antagonists for Pulmonary Fibrosis by Variation in Aryl Substituents. , 2014, ACS medicinal chemistry letters.
[41] J. Berlin,et al. A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.
[42] K. Aldape,et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. , 2014, The Lancet. Oncology.
[43] Rhian Gabe,et al. Therapeutic Targeting of Integrin αvβ6 in Breast Cancer , 2014, Journal of the National Cancer Institute.
[44] O. Brand,et al. Selective Targeting of TGF-β Activation to Treat Fibroinflammatory Airway Disease , 2014, Science Translational Medicine.
[45] B. Hinz,et al. Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contraction. , 2014, Cardiovascular research.
[46] H. Ueno,et al. Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinoma , 2014, Investigational New Drugs.
[47] L. Donnelly,et al. Challenges for inhaled drug discovery and development: Induced alveolar macrophage responses. , 2014, Advanced drug delivery reviews.
[48] J. Verweij,et al. Determining the optimal dose in the development of anticancer agents , 2014, Nature Reviews Clinical Oncology.
[49] José Luis Alonso,et al. Structural basis for pure antagonism of integrin αVβ3 by a high affinity form of fibronectin , 2014, Nature Structural &Molecular Biology.
[50] L. Patterson,et al. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists. , 2014, Journal of medicinal chemistry.
[51] A. Perkins,et al. Preclinical SPECT/CT Imaging of αvβ6 Integrins for Molecular Stratification of Idiopathic Pulmonary Fibrosis , 2013, The Journal of Nuclear Medicine.
[52] A. Kestranek,et al. Chemiluminescent Nitrogen Detection (CLND) to Measure Kinetic Aqueous Solubility , 2013, Current protocols in chemical biology.
[53] H. Kessler,et al. Integrin modulators: a patent review , 2013, Expert opinion on therapeutic patents.
[54] S. Barry,et al. A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo , 2013, Oncogene.
[55] Liang-Shang Gan,et al. Plasma protein binding: from discovery to development. , 2013, Journal of pharmaceutical sciences.
[56] H. Kessler,et al. Tumor Targeting via Integrin Ligands , 2013, Front. Oncol..
[57] D. Griggs,et al. Selective αv integrin depletion identifies a core, targetable molecular pathway that regulates fibrosis across solid organs , 2013, Nature Medicine.
[58] Mark E Bunnage,et al. Target validation using chemical probes. , 2013, Nature chemical biology.
[59] R. Guha,et al. Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and-Independent Luciferases: Implications for Reporter-Gene Assays , 2013, PloS one.
[60] N. Bogdanova,et al. A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] D. Morel,et al. In vitro investigation of integrin-receptor antagonist-induced vascular toxicity in the mouse. , 2013, Toxicology in vitro : an international journal published in association with BIBRA.
[62] D. Sheppard,et al. Absence of integrin αvβ3 enhances vascular leak in mice by inhibiting endothelial cortical actin formation. , 2012, American journal of respiratory and critical care medicine.
[63] G. Minniti,et al. Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results. , 2012, Anticancer research.
[64] S. Goodman,et al. Integrins as therapeutic targets. , 2012, Trends in pharmacological sciences.
[65] A. Pavlick,et al. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma , 2012, Investigational New Drugs.
[66] Ken Grime,et al. Optimisation of DMPK by the inhaled route: challenges and approaches. , 2012, Current drug metabolism.
[67] Y. Vugmeyster,et al. Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges. , 2012, World journal of biological chemistry.
[68] B. Coller,et al. Structure-Guided Design of a High-Affinity Platelet Integrin αIIbβ3 Receptor Antagonist That Disrupts Mg2+ Binding to the MIDAS , 2012, Science Translational Medicine.
[69] D. Cella,et al. Health-related quality of life among patients with metastatic melanoma: results from an international phase 2 multicenter study , 2012, Melanoma research.
[70] E. Novellino,et al. Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site. , 2012, Journal of medicinal chemistry.
[71] S. Robinson,et al. The role of β3-integrins in tumor angiogenesis: context is everything. , 2011, Current opinion in cell biology.
[72] M. Marahiel,et al. Introducing lasso peptides as molecular scaffolds for drug design: engineering of an integrin antagonist. , 2011, Angewandte Chemie.
[73] Hannu Raunio,et al. Prodrugs—from Serendipity to Rational Design , 2011, Pharmacological Reviews.
[74] D. Cheresh,et al. αV integrins in angiogenesis and cancer. , 2011, Cold Spring Harbor perspectives in medicine.
[75] Darren V S Green,et al. Getting physical in drug discovery II: the impact of chromatographic hydrophobicity measurements and aromaticity. , 2011, Drug discovery today.
[76] F. Prinz,et al. Believe it or not: how much can we rely on published data on potential drug targets? , 2011, Nature Reviews Drug Discovery.
[77] P. Fracasso,et al. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer , 2011, Investigational New Drugs.
[78] D. Schadendorf,et al. A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma , 2011, British Journal of Cancer.
[79] S. Bender,et al. Dual functional monoclonal antibody PF-04605412 targets integrin alpha5beta1 and elicits potent antibody-dependent cellular cytotoxicity. , 2010, Cancer research.
[80] Edward H. Kerns,et al. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery , 2010, Nature Reviews Drug Discovery.
[81] Horst Kessler,et al. Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation , 2010, Anti-cancer agents in medicinal chemistry.
[82] Marian Brennan,et al. Integrins as therapeutic targets: lessons and opportunities , 2010, Nature Reviews Drug Discovery.
[83] M. Dolenc,et al. Small molecule antagonists of integrin receptors. , 2010, Current medicinal chemistry.
[84] Chris J Scotton,et al. Bleomycin revisited: towards a more representative model of IPF? , 2010, American journal of physiology. Lung cellular and molecular physiology.
[85] Ian Collins,et al. Probing the Probes: Fitness Factors For Small Molecule Tools , 2010, Chemistry & biology.
[86] C. Curti,et al. Targeting αvβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides , 2010 .
[87] J. Sosman,et al. A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin αvβ3, ± dacarbazine in patients with stage IV metastatic melanoma , 2010, Cancer.
[88] M. Campone,et al. Evaluation of the safety, pharmacokinetics and treatment effects of an ανβ3 integrin inhibitor on bone turnover and disease activity in men with hormone‐refractory prostate cancer and bone metastases , 2010, Asia-Pacific journal of clinical oncology.
[89] A. Sonnenberg,et al. Integrin–TGF‐β crosstalk in fibrosis, cancer and wound healing , 2010 .
[90] A. Adamis,et al. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. , 2009, Archives of ophthalmology.
[91] M. Serra,et al. Small molecule integrin antagonists in cancer therapy. , 2009, Mini reviews in medicinal chemistry.
[92] R. Stupp,et al. Will integrin inhibitors have proangiogenic effects in the clinic? , 2009, Nature Medicine.
[93] E. Novellino,et al. Breaking the dogma of the metal-coordinating carboxylate group in integrin ligands: introducing hydroxamic acids to the MIDAS to tune potency and selectivity. , 2009, Angewandte Chemie.
[94] H. Kessler,et al. Bruch mit dem Dogma metallkoordinierender Carbonsäuren in Integrinliganden: Änderung von Selektivität und Aktivität durch Hydroxamsäuren als MIDAS‐Binder , 2009 .
[95] D. Stupack,et al. Agonizing integrin antagonists? , 2009, Cancer cell.
[96] J. Norman,et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors , 2009, Nature Medicine.
[97] Simon J. F. Macdonald,et al. Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet? , 2009, J. Chem. Inf. Model..
[98] R. Fässler,et al. Genetic and cell biological analysis of integrin outside-in signaling. , 2009, Genes & development.
[99] A. Tolcher,et al. Volociximab, a Chimeric Monoclonal Antibody that Specifically Binds α5β1 Integrin: A Phase I, Pharmacokinetic, and Biological Correlative Study , 2008, Clinical Cancer Research.
[100] R. Mirimanoff,et al. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. , 2008, Cancer research.
[101] J. Hughes,et al. Physiochemical drug properties associated with in vivo toxicological outcomes. , 2008, Bioorganic & medicinal chemistry letters.
[102] D. Shaw,et al. Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth , 2008, Clinical Cancer Research.
[103] S. Mousa,et al. Studies with an Orally Bioavailable αV Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.
[104] C. Schubert,et al. Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies. , 2008, The Journal of organic chemistry.
[105] P. Leeson,et al. The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.
[106] William F. DeGrado,et al. Small Molecule Inhibitors of Integrin α2β1 , 2007 .
[107] S. Rodan,et al. Involvement of αvβ3 integrins in osteoclast function , 2007, Journal of Bone and Mineral Metabolism.
[108] J. Sutcliffe,et al. Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography. , 2007, Cancer research.
[109] U. Reimer,et al. Design and Synthesis of a New Class of Selective Integrin α5β1 Antagonists , 2007 .
[110] Robert A. Beckman,et al. Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[111] M. Waring,et al. A quantitative assessment of hERG liability as a function of lipophilicity. , 2007, Bioorganic & medicinal chemistry letters.
[112] D. Sheppard,et al. Integrin αvβ5 Regulates Lung Vascular Permeability and Pulmonary Endothelial Barrier Function , 2007 .
[113] L. P. Mašič. Arginine mimetic structures in biologically active antagonists and inhibitors. , 2006, Current medicinal chemistry.
[114] Dahua Zhang,et al. Effects of a monoclonal anti-αvβ3 integrin antibody on blood vessels—A pharmacodynamic study , 2006, Investigational New Drugs.
[115] D. Shaw,et al. A non–RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo , 2006, Molecular Cancer Therapeutics.
[116] B. González,et al. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector , 2006, International journal of cancer.
[117] H. Kessler,et al. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. , 2006, Current pharmaceutical design.
[118] Juan J. Marugan,et al. Original articleNovel potent and selective αvβ3/αvβ5 integrin dual antagonists with reduced binding affinity for human serum albumin , 2006 .
[119] T. Penning,et al. Synthesis of pyrazoles and isoxazoles as potent αvβ3 receptor antagonists , 2006 .
[120] P. Carter. Potent antibody therapeutics by design , 2006, Nature Reviews Immunology.
[121] Shobha N. Bhattachar,et al. Evaluation of the chemiluminescent nitrogen detector for solubility determinations to support drug discovery. , 2006, Journal of pharmaceutical and biomedical analysis.
[122] M. Ishikawa,et al. Tricyclic pharmacophore-based molecules as novel integrin αvβ3 antagonists. Part 2: Synthesis of potent αvβ3/αIIbβ3 dual antagonists , 2006 .
[123] R. Willette,et al. SB-267268, a nonpeptidic antagonist of alpha(v)beta3 and alpha(v)beta5 integrins, reduces angiogenesis and VEGF expression in a mouse model of retinopathy of prematurity. , 2006, Investigative ophthalmology & visual science.
[124] Hongwei Wu,et al. Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties , 2006 .
[125] M. Jinnin,et al. Increased Expression of Integrin αvβ5 Induces the Myofibroblastic Differentiation of Dermal Fibroblasts , 2006 .
[126] J. Bennett,et al. Structure and function of the platelet integrin αIIbβ3 , 2005 .
[127] Jens Eickhoff,et al. Phase I Trial of a Monoclonal Antibody Specific for αvβ3 Integrin (MEDI-522) in Patients with Advanced Malignancies, Including an Assessment of Effect on Tumor Perfusion , 2005, Clinical Cancer Research.
[128] M. Dolenc,et al. Dual antagonists of integrins. , 2005, Current medicinal chemistry.
[129] G. Gordon,et al. Activation of focal adhesion kinase in human lung cancer cells involves multiple and potentially parallel signaling events , 2005, Journal of cellular and molecular medicine.
[130] C. Leu,et al. Nonpeptide αvβ3 antagonists : identification of potent, chain-shortened 7-oxo RGD mimetics , 2005 .
[131] B. Tomczuk,et al. Design, Synthesis, and Biological Evaluation of Novel Potent and Selective αvβ3/αvβ5 Integrin Dual Inhibitors with Improved Bioavailability. Selection of the Molecular Core , 2005 .
[132] G. Leo,et al. 1,2,3,4-Tetrahydroquinoline-containing αvβ3 integrin antagonists with enhanced oral bioavailability , 2004 .
[133] Dana L. Johnson,et al. Piperidine-containing β-arylpropionic acids as potent antagonists of αvβ3/αvβ5 integrins , 2004 .
[134] R. Hynes. The emergence of integrins: a personal and historical perspective. , 2004, Matrix biology : journal of the International Society for Matrix Biology.
[135] D. Huryn,et al. The identification and optimization of orally efficacious, small molecule VLA-4 antagonists. , 2004, Current topics in medicinal chemistry.
[136] C. Leu,et al. Nonpeptide αvβ3 antagonists. Part 9: Improved pharmacokinetic profile through the use of an aliphatic, des-amide backbone , 2004 .
[137] J. Marugan,et al. Design, synthesis, and biochemical evaluation of novel alpha V beta 3 integrin ligands. , 2004, Bioorganic & medicinal chemistry letters.
[138] P. Coleman,et al. Nonpeptide αvβ3 Antagonists. Part 11: Discovery and Preclinical Evaluation of Potent αvβ3 Antagonists for the Prevention and Treatment of Osteoporosis , 2004 .
[139] E. Novellino,et al. Human Integrin αvβ5: Homology Modeling and Ligand Binding , 2004 .
[140] M. Trikha,et al. CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.
[141] S. Andronati,et al. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications. , 2004, Current medicinal chemistry.
[142] K. Simon,et al. Function-blocking Integrin αvβ6 Monoclonal Antibodies , 2004, Journal of Biological Chemistry.
[143] P. Coleman,et al. Non-peptide αvβ3 antagonists. Part 7: 3-Substituted tetrahydro-[1,8]naphthyridine derivatives , 2004 .
[144] L. Tan,et al. An efficient synthesis of an alphavbeta3 antagonist. , 2004, The Journal of organic chemistry.
[145] B. Ma,et al. Renal elimination of a novel and potent αvβ3 integrin antagonist in animals , 2004 .
[146] C. Leu,et al. Non-peptide αvβ3 antagonists: Identification of potent, chain-shortened RGD mimetics that incorporate a central pyrrolidinone constraint , 2003 .
[147] M. Abraham,et al. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. , 2003, Journal of pharmaceutical sciences.
[148] D. Sheppard,et al. Transforming Growth Factor-β-Dependent and -Independent Pathways of Induction of Tubulointerstitial Fibrosis in β6−/− Mice , 2003 .
[149] P. Coleman,et al. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. , 2003, Journal of medicinal chemistry.
[150] Horst Kessler,et al. Docking studies on αvβ3 integrin ligands: Pharmacophore refinement and implications for drug design , 2003 .
[151] Timothy A. Springer,et al. Therapeutic antagonists and conformational regulation of integrin function , 2003, Nature Reviews Drug Discovery.
[152] C. Leu,et al. Non-Peptide αvβ3 antagonists. Part 6: Design and synthesis of αvβ3 antagonists containing a pyridone or pyrazinone central scaffold , 2003 .
[153] J. Verweij,et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours , 2003 .
[154] L. Ellis,et al. Inhibition of integrin α5β1 function with a small peptide (ATN‐161) plus continuous 5‐FU infusion reduces colorectal liver metastases and improves survival in mice , 2003, International journal of cancer.
[155] K. Ward,et al. Phenylbutyrates as potent, orally bioavailable vitronectin receptor (integrin αvβ3) antagonists , 2003 .
[156] A. Kling,et al. Design and synthesis of 1,5- and 2,5-substituted tetrahydrobenzazepinones as novel potent and selective integrin α V β 3 antagonists , 2003 .
[157] Andrea Vaupel,et al. Biphenyls as potent vitronectin receptor antagonists. Part 2: biphenylalanine ureas. , 2003, Bioorganic & medicinal chemistry letters.
[158] R. Volante,et al. Highly regioselective Friedländer annulations with unmodified ketones employing novel amine catalysts: syntheses of 2-substituted quinolines, 1,8-naphthyridines, and related heterocycles. , 2003, The Journal of organic chemistry.
[159] S. Barry,et al. The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. , 2003, The Biochemical journal.
[160] L. Schnapp,et al. Integrin α8β1 mediates adhesion to LAP-TGFβ1 , 2002, Journal of Cell Science.
[161] R. Wilder,et al. Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases , 2002, Annals of the rheumatic diseases.
[162] Junichi Takagi,et al. Global Conformational Rearrangements in Integrin Extracellular Domains in Outside-In and Inside-Out Signaling , 2002, Cell.
[163] P. Coleman,et al. Non-Peptide αvβ3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shortened RGD Mimetics , 2002 .
[164] Kathleen R. Lamborn,et al. Cilengitide Targeting of αvβ3 Integrin Receptor Synergizes with Radioimmunotherapy to Increase Efficacy and Apoptosis in Breast Cancer Xenografts , 2002 .
[165] P. Coleman,et al. Ligands to the integrin receptor αvβ3 , 2002 .
[166] E. Lazarides,et al. Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual alpha(4)beta(7)/alpha(4)beta(1) integrin antagonist. , 2002, Bioorganic & medicinal chemistry.
[167] Stephen R. Johnson,et al. Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.
[168] Klaus Schulten,et al. A structural model for force regulated integrin binding to fibronectin's RGD-synergy site. , 2002, Matrix biology : journal of the International Society for Matrix Biology.
[169] E. Topol,et al. Glycoprotein IIb/IIIa antagonists - from bench to practice , 2002, Cellular and Molecular Life Sciences CMLS.
[170] Horst Kessler,et al. Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins , 2002 .
[171] P. Coleman,et al. Non-peptide αvβ3 antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl β-amino acids as aspartic acid replacements , 2002 .
[172] M. Okada,et al. Novel Malonamide Derivatives as αvβ3 Antagonists. Syntheses and Evaluation of 3-(3-Indolin-1-yl-3-oxopropanoyl)aminopropanoic Acids on Vitronectin Interaction with αvβ3 , 2001 .
[173] Horst Kessler,et al. Solid-Phase Synthesis of a Nonpeptide RGD Mimetic Library: New Selective αvβ3 Integrin Antagonists , 2001 .
[174] H. van de Waterbeemd,et al. Property-based design: optimization of drug absorption and pharmacokinetics. , 2001, Journal of medicinal chemistry.
[175] K. Ward,et al. Antagonism of the Osteoclast Vitronectin Receptor with an Orally Active Nonpeptide Inhibitor Prevents Cancellous Bone Loss in the Ovariectomized Rat , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[176] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[177] F. Mitjans,et al. In vivo therapy of malignant melanoma by means of antagonists of αv integrins , 2000 .
[178] R. Willette,et al. Identification and in vivo efficacy of small-molecule antagonists of integrin αvβ3 (the vitronectin receptor) , 2000 .
[179] R. Scarborough,et al. Platelet glycoprotein IIb-IIIa antagonists as prototypical integrin blockers: novel parenteral and potential oral antithrombotic agents. , 2000, Journal of medicinal chemistry.
[180] W. F. Hoffman,et al. Nonpeptide αvβ3 Antagonists. 1. Transformation of a Potent, Integrin-Selective αIIbβ3 Antagonist into a Potent αvβ3 Antagonist , 2000 .
[181] Li Zhang,et al. Ligand Binding to Integrins* , 2000, The Journal of Biological Chemistry.
[182] F. Mitjans,et al. Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells. , 2000, European journal of cell biology.
[183] D. Rockey,et al. Expression of the Integrin α8β1 during Pulmonary and Hepatic Fibrosis , 2000 .
[184] G. Hartman,et al. αvβ3 Integrin antagonists as inhibitors of bone resorption , 2000 .
[185] S. Barry,et al. A Regulated Interaction between α5β1 Integrin and Osteopontin , 2000 .
[186] P. Jadhav,et al. Isoxazolines as Potent Antagonists of the Integrin αvβ3 , 2000 .
[187] Horst Kessler,et al. N-methylated cyclic RGD peptides as highly active and selective αvβ3 integrin antagonists , 1999 .
[188] N. Kaminski,et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. , 1999, Cell.
[189] R. Jordan,et al. Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and αvβ3 Integrins , 1998 .
[190] William F. Westlin,et al. A Peptidomimetic Antagonist of the Integrin αvβ3 Inhibits Leydig Cell Tumor Growth and the Development of Hypercalcemia of Malignancy , 1998 .
[191] T. Harada,et al. Development of the new potent non-peptide gpIIb/IIIa antagonist NSL-95301 by utilizing combinatorial technique , 1997 .
[192] Chandra L. Theesfeld,et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[193] J. Engel,et al. Demonstration of non‐linear detection in ELISA resulting in up to 1000‐fold too high affinities of fibronogen binding to integrin αIIbβ3 , 1995 .
[194] D. Cheresh,et al. Integrin α v β 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels , 1994, Cell.
[195] R. Gould,et al. Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. , 1994, Journal of medicinal chemistry.
[196] E. Wayner,et al. Integrins alpha v beta 3 and alpha v beta 5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface , 1991, The Journal of cell biology.
[197] W. Carter,et al. Identification of multiple cell adhesion receptors for collagen and fibronectin in human fibrosarcoma cells possessing unique alpha and common beta subunits , 1987, The Journal of cell biology.
[198] Richard O. Hynes,et al. Integrins: A family of cell surface receptors , 1987, Cell.
[199] R. Hynes,et al. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin , 1986, Cell.
[200] K. Ley,et al. Integrin-based therapeutics : biological basis , clinical use and new drugs , 2016 .
[201] H. Juhl,et al. Precision Cut Cancer Tissue Slices in Anti-Cancer Drug Testing - , 2015 .
[202] C. Belani,et al. Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[203] David A. Cheresh,et al. Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.
[204] A. Tolcher,et al. Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients , 2009, Cancer Chemotherapy and Pharmacology.
[205] Nicola J. Rinaldi,et al. Partial Inhibition of Integrin αvβ6 Prevents Pulmonary Fibrosis without Exacerbating Inflammation , 2008 .
[206] Peter R. Byron,et al. Inhaling medicines: delivering drugs to the body through the lungs , 2007, Nature Reviews Drug Discovery.
[207] R. Dubridge,et al. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. , 2006, Journal of experimental therapeutics & oncology.
[208] J. Yergey,et al. IN VITRO AND IN VIVO METABOLISM OF A POTENT AND SELECTIVE INTEGRIN v 3 ANTAGONIST IN RATS , DOGS , AND MONKEYS , 2004 .
[209] H. Berman,et al. Electronic Reprint Biological Crystallography the Protein Data Bank Biological Crystallography the Protein Data Bank , 2022 .
[210] Mulin Jun Li,et al. Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .